Substances and methods prohibited at all times (In- and Out-of-Competition)
S1 Anabolic Agents
• Dihydrotestosterone was renamed to its International Non-proprietary Name (INN) (androstanolone).
• 1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one) was added in S1.a as an example of exogenous anabolic steroid.
• LGD-4033 and RAD140 were added as further examples of SARMs.
S2 Peptide Hormones, Growth Hormones, Growth Factors, related substances and Mimetics
• For clarity and accuracy Section S2 was reorganized.
• ARA290 was removed as an example in this section because current literature suggests it does not meet inclusion criteria.
• Desmorelin, goserelin, nafarelin and triptorelin were added as examples of 2.1.
• Growth Hormone fragments were included in 2.3 with AOD-9604 and hGH 176-191 added as examples;
• CJC-1293 was added as example of GHRH and tabimorelin as a further example of GH secretagogue.
• GHRP-1, -3, -4, and -5 were added as examples of GHRP.
• Thymosin- β4 and its derivatives, e. g. TB-500, were added as example of prohibited growth factors.
• Cobalt: It is re-iterated that vitamin B12, which contains cobalt, is not prohibited.
• Dosing parameters of salbutamol were revised to make it clear that divided doses of salbutamol may not exceed 800 micrograms over any 12 hours.
• Tulobuterol was added as an example.
• The statement on the urinary thresholds was improved.
S4 Hormone and Metabolic Modulators
• Clomifene is now stated by its INN.
• In the absence of an INN, the IUPAC name of GW1516, 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl) thiazol-5-yl)methylthio)phenoxy) acetic acid as well as an alternative name (GW501516) were included.
• SR9009, a Rev-Erb-α agonist, was added as an example of Activators of the AMP-activated protein kinase (AMPK).
S5 Diuretics and Masking Agents
• In consideration of the information published in scientific articles since 2012 that particularly addresses the ability of glycerol to influence the athlete‘s plasma volume and parameters of the Athlete Biological Passport (ABP), the magnitude of glycerol-derived effects is regarded as minimal. Therefore, glycerol has been removed from the Prohibited List.
M2 Chemical and Physical Manipulation
• M2.2: the permitted volume and timing of intravenous infusions were changed from infusions of no more than 50 mL per 6-hour period to no more than a total of 100 mL per 12-hour period in order to allow greater flexibility for the safe administration of non-prohibited therapeutic substances, for example, iron.
• To reflect medical practice, “hospital admissions” has been changed to “hospital treatments” and “clinical investigations” has been clarified as “clinical diagnostic investigations”.
M3 Gene Doping
• The definition has been revised to include current and emerging gene manipulating technologies.
Substances and Methods Prohibited In-Competition
• 1,3-Dimethylbutylamine was added as an example. This substance can be found in some dietary supplements.
• The category Cannabimimetics, e.g. “Spice, JWH-018, JWH-073, HU210” was changed to “synthetic cannabinoids, e.g. Δ9-tetrahydrocannabinol (THC) and other cannabimimetics”. The synthetic cannabinoids are one of the main classes of novel psychoactive substances that have constantly emerging new drugs and changing availability. The previous list of examples continues to be prohibited, but are currently used less commonly. “Other cannabimimetics” replaced these examples.
• Cannabidiol is no longer prohibited. Synthetic cannabidiol is not a cannabimimetic; however, cannabidiol extracted from cannabis plants may also contain varying concentrations of THC, which remains a prohibited substance.
• Examples of commonly used glucocorticoids were added for greater clarity.
The following were added to evaluate misuse in sport:
• 2-ethylsulfanyl-1H-benzimidazole (bemitil) in- and out-of-competition
• Hydrocodone in-competition.
Mitragynine and telmisartan were removed from the Monitoring Program because the required information on prevalence was obtained.